News

FDA accepts filing of NDA for Lynparza for patients with metastatic castration-resistant prostate cancer . AstraZeneca + Merck Inc.

Read time: 1 mins

Published:21st Jan 2020

AstraZeneca and MSD Inc.,announced that a supplemental New Drug Application for Lynparza (olaparib) has been accepted and granted Priority Review in the US for patients with metastatic castration-resistant prostate cancer (mCRPC) and deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene mutations, who have progressed following prior treatment with a new hormonal agent. A Prescription Drug User Fee Act (PDUFA) date is set for the second quarter of 2020. The Priority Review by the FDA is based on results from the Phase III PROfound trial, which were presented during the Presidential Symposium at the 2019 European Society of Medical Oncology congress.

Condition: Prostate Cancer

Type: drug

Responding to unmet needs for metastatic castration-resistant prostate cancer

Learning Zone Homepage

mCRPC in focus

Unmet needs in the management of mCRPC, with a focus on treatments.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Positive CHMP opinion for Xtandi (enzaltamide)in additional recurrent early prostate cancer treatment setting.- Astellas.

Astellas Pharma Inc. announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of Xtandi (enzalutamide) as monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high risk biochemical recurrent (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC) who are unsuitable for salvage radiotherapy.

1 mins

Drug news

Detailed results of phase III CONTACT-02 pivotal trial evaluating cabozantinib + atezolizumab in metastatic castration-resistant prostate cancer presented at ASCO GU 2024

Exelixis, Inc. announced detailed results from CONTACT-02, a phase III pivotal study evaluating cabozantinib (Cabometyx) in combination with atezolizumab compared with a second novel hormonal therapy (NHT) in patients with metastatic castration-resistant prostate cancer (mCRPC) and measurable extra-pelvic soft tissue disease who have progressed on one prior NHT

2 min

Drug news

European Commission approves Talzenna (talazoparib)+ Xtandi (enzalutamide) for adult patients with metastatic castration-resistant prostate cancer.- Pfizer.

Pfizer Inc. announced that the European Commission (EC) has approved Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide), for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.

1 min

See all news